Renaissance Technologies
PBLA

Renaissance Technologies’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Renaissance Technologies’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$4K – 4588
2022
Q4 		$4K Buy
+2
New +$6.81K ﹤0.01% 4070

Other funds holding PBLA

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Renaissance Technologies's PBLA Position: Q1 2023 in Review

Renaissance Technologies sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2023, closing a stake of 2 shares — an estimated $4K sold.

Renaissance Technologies first reported a position in PBLA in Q4 2022 and held it in 1 quarter. The position peaked at $4K in Q4 2022. 15 funds tracked by Wall St. Rank hold PBLA as of Q1 2023.

  • Renaissance Technologies reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Renaissance Technologies sold 2 Panbela Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4K.
  • Renaissance Technologies first reported a position in Panbela Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Renaissance Technologies's Panbela Therapeutics, Inc. Common Stock position peaked at $4K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.